CMPXCompass Therapeutics
About Compass Therapeutics
Compass Therapeutics (NASDAQ:CMPX) is a biotechnology firm deeply immersed in the discovery and development of antibody therapeutics aimed at treating cancer, autoimmune disorders, and other diseases. The company leverages its proprietary StitchMabs™ and common light chain platforms to engineer novel biologic agents. Compass Therapeutics focuses on advancing its robust pipeline of therapeutic candidates, including lead assets that show promising preclinical and early clinical results for a range of medical conditions. The ultimate objective of Compass Therapeutics is to transform the landscape of treatment options available to patients suffering from severe diseases by bringing innovative and effective therapies to market.
What is CMPX known for?
Snapshot
Public US
Ownership
2014
Year founded
32
Employees
Boston, United States
Head office
1 of 5
US Rank
Unknown
Sector
N/A
Sector rank
Loading Map...
Operations
All Locations
Boston, US
Produtos e/ou serviços de Compass Therapeutics
- CTx-471, a next-generation checkpoint inhibitor designed to stimulate the immune system to target and kill cancer cells.
- CTX-8371, a dual-action PI3K and HDAC inhibitor aimed at treating solid tumors.
- Patient-derived xenograft (PDX) models and in-house developed tumor cell lines for predictive efficacy testing and personalized medicine research.
equipe executiva do Compass Therapeutics
- Dr. Thomas J. Schuetz M.D., Ph.D.CEO & Vice Chairman
- Mr. Barry Shin J.D., M.B.A.Chief Financial Officer
- Mr. Jonathan E. Anderman J.D.Senior VP, General Counsel & Corporate Secretary
- Mr. Neil L. Lerner CPASenior VP & Chief Accounting Officer
- Anna GiffordCommunications Manager
- Ms. Karin Herrera B.A.Senior VP & Head of Clinical Operations
- Dr. James Kranz Ph.D.VP and Head of Chemistry Manufacturing & Controls
- Dr. Cynthia A. Sirard M.D.Chief Medical Officer
- Mr. Arjun Prasad M.B.A., M.P.H.Chief Commercial Officer